HAB Pharmaceuticals & Research Limited Targets ₹3,000 Crore Revenue by 2030 with Manufacturing and GLP-1 Expansion
HAB Pharmaceuticals & Research Limited is targeting revenues of ₹2,500–₹3,000 crore by 2030 by expanding its manufacturing footprint, strengthening research and development, diversifying its product portfolio, and accelerating its global presence. The strategy is supported…
Read More







